SpectraLIT, a Compact Development Kit for Spectral Analysis Applications Introduced by Newsight Imaging

Newsight Imaging, the CMOS image sensor chip maker for 3D machine vision and spectral analysis applications announced the release of its SpectraLIT, a compact development kit suitable for testing Newsight technology and developing proof-of-concept devices for the healthcare and food & beverage industries or other liquids analysis.

SpectraLIT™ is a development kit based on Newsight’s spectrometer-on- chip. It allows for spectral profiling of substances in wavelengths between 400 to 700 nm in a matter of seconds. The next generation of SpectraLIT™️ will be able to support wavelengths between 400 to 1100 nm. The kit will allow diagnostic and analytical companies a fast market introduction of a portable, and low-cost diagnosis device. SpectraLIT is controlled by a Windows-based demo SW that displays, analyzes and stores the spectral profiles of the tested substance.

SpectraLIT uses standard cuvettes, which are easily inserted through a slide covered by a top lid, allowing full isolation of the tested substance from any external ambient light.

Using a special developed algorithm, SpectraLIT can compare the tested substance’s spectral profiles to profiles stored in a local database, allowing detection and identification of matching substances previously analyzed by SpectraLIT.

Newsight is now offering its potential partners to develop its POC based on SpectraLIT™. Upon achieving successful implementation, Newsight is offering its partner to license the technology, acquire the spectral chips or use a ready-made module to build their own game changing device.

On June 16th, 16:00 pm CEST, Newsight will conduct a free live webinar demonstrating SpectraLIT™ for potential future partners who will be interested in building an immediate, portable, and affordable detection device based on spectral profiling technology. To register here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”